Investor Alert: Pomerantz Law Firm Investigates Alleged Securities Fraud at Medline Inc.
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by Medline Inc. (NASDAQ: MDLN) and its officers or directors on behalf of investors. The investigation follows an FDA warning letter issued in June 2026, which cited significant violations related to pharmaceutical manufacturing standards at the company's facilities. The FDA found that Medline failed to investigate discrepancies in product quality adequately. Following this news, Medline’s stock price dropped by $2.56 per share (7.16%) on June 2, 2026. Further concerns arose during an August earnings call where the company acknowledged remediation efforts had led to financial losses, causing another drop of $5.38 per share (12.79%) on August 5. Pomerantz LLP is a well-known law firm specializing in corporate and securities litigation with offices across multiple global locations.
Tickers: $MDLN
Topics: class action lawsuit FDA warning letter stock price drop